Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

Zukin1, Mauro; Gondim2, Victor; Shimada3, Andrea Kazumi; Lima4, Ellias Magalhães e Abreu; Mathias5,6, Clarissa; Barra7, Williams Fernandes; Junior8,9, William Nassib William; Padoan2, Mônica; Bittencourt3a, Yuri; Yamamura8, Rosely; Silva10, Carlos Eduardo Baston; Rossato11, Letícia de Jesus; Monteiro1, Caio de Almeida; Jesus12, Rafaela Gomes de; Gössling12, Gustavo; Gelatti13, Ana Caroline Zimmer

171
Views

Back to summary

Open Access

Peer-Reviewed
Artigo Original

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

Mauro Zukin1, Victor Gondim2, Andrea Kazumi Shimada3, Ellias Magalhães e Abreu Lima4, Clarissa Mathias5,6, Williams Fernandes Barra7, William Nassib William Junior8,9, Mônica Padoan2, Yuri Bittencourt3a, Rosely Yamamura8, Carlos Eduardo Baston Silva10, Letícia de Jesus Rossato11, Caio de Almeida Monteiro1, Rafaela Gomes de Jesus12, Gustavo Gössling12, Ana Caroline Zimmer Gelatti13

1. Oncologia D'Or e Instituto D'Or, Rio de Janeiro (RJ), Brasil.
2. Instituto Américas, Rio de Janeiro (RJ), Brasil.
3. Hospital Sírio-Libanês, São Paulo (SP), Brasil.
4. Instituto Mario Penna, Belo Horizonte (MG), Brasil.
5. Oncoclínicas, Salvador (BA), Brasil.
6. Hospital Santa Izabel, Salvador (BA), Brasil.
7. Universidade Federal do Pará, Núcleo de Pesquisa em Oncologia, Belém (PA), Brasil.
8. BP - A Beneficência Portuguesa de
São Paulo, São Paulo (SP), Brasil.
9. Grupo Oncoclínicas, São Paulo (SP), Brasil.
10. Hospital de Amor, Barretos (SP), Brasil.
11. Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre (RS), Brasil.
12. Latin American Cooperative Oncology Group (LACOG), Porto Alegre (RS), Brasil.
13. Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre (RS), Brasil.
Submitted: 17 July 2024.
Accepted: 13 November 2024.
Study carried out at the Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro (RJ), Brasil.

Correspondence to:
Mauro Zukin. Oncologia D'Or e Instituto D'Or, Rio de Janeiro, RJ, Brasil. IDOR - Instituto D'Or de Pesquisa e Ensino. Rua Diniz Cordeiro 30, CEP 22281-100, Botafogo, Rio de Janeiro (RJ), Brasil. E-mail: zukinmauro@gmail.com
Financial support:This study was funded by AstraZeneca. The funder had no role in data collection, analysis, interpretation, or writing of the manuscript.

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

Related articles

Indexes

Official publication

Newsletters